ARISTO Pharmaceuticals

What ARISTO Pharmaceuticals does

Aristo Pharmaceuticals Private Limited is an Indian-branded generic pharmaceutical formulations company founded in 1971 by Mahendra Prasad and headquartered in Mumbai. The company manufactures and markets a broad portfolio of pharmaceutical products across 15+ therapeutic categories including anti-infectives (Rs 2,518.87 Cr), gastrointestinal (Rs 1,068.49 Cr), cardiac, respiratory, anti-diabetic, gynaecological, pain/analgesics, and neuro/CNS segments. Its core brands — Monocef, Pantop, Mikacin, Pantop-D, Monocef-SB, Montaz, Monocef-O, Mero, Mega-CV, and Aristozyme — collectively represent over Rs 2,800 Crores in revenue, with ten brands ranked in the top 300 of the Indian Pharma Market. Aristo has introduced more than 21 first-in-India formulations, demonstrating an innovation orientation within the domestic generics space, and recently expanded into probiotics via a technical tie-up with Chr. Hansen, Denmark for the ProGG L. rhamnosus GG brand.

The company operates with 7 marketing divisions and a front line sales force of 5,100 medical representatives that promote its portfolio to healthcare providers across India through the stockist secondary sales channel. Revenue is generated primarily through one-time product sales with pricing regulated by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs Prices Control Order 2013. Per IQVIA MAT March'25 data, Aristo reported revenue of Rs 5,700.38 Crores, a 2.90% market share, rank 11 in the Indian Pharma Market (overall) and rank 3 in its covered market. The company has achieved a 5-year CAGR of 10.76%, was ranked 5th on CAGR among top 15 Indian pharma companies, and holds rank 5 in the SMSRC prescription audit, reflecting medical fraternity trust.

Aristo is a privately held, family-owned enterprise with no external institutional investor ownership signals identified; the company is subject to an ongoing inheritance dispute over the INR 40,000 crore Aristo empire being adjudicated in the Delhi High Court. Its operations are concentrated in the Indian domestic market with no disclosed international expansion. The company also faces regulatory exposure: the Enforcement Directorate is investigating supply chain practices regarding codeine-based cough syrups, with Aristo among the companies whose records have been sought.

Name

ARISTO Pharmaceuticals

Legal name

Aristo Pharmaceuticals Private Limited

Website

https://aristopharma.co.in

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Aristo Pharmaceuticals is a privately held Indian generic pharmaceutical company that manufactures and markets branded formulations across 15+ therapeutic categories, including anti-infectives, gastrointestinal, cardiac, and respiratory segments, serving healthcare providers and patients across India through a 5,100-person sales force and stockist distribution network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Pharmaceutical formulations
• Generic medicines
• Antibiotic medications
• Probiotic supplements
• Cardiac diabetic drugs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of branded pharmaceutical formulations across multiple therapeutic segments including Anti-Infectives, Gastro Intestinal, Cardiac, Respiratory, Anti Diabetic, Gynaecological, Pain/Analgesics, Neuro/CNS, Vitamins/Minerals/Nutrients, and other categories through stockist secondary sales channel.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Aristo Pharmaceuticals manufactures and markets branded and generic pharmaceutical formulations across 15+ therapeutic segments including anti-infectives, gastrointestinal, cardiac, respiratory, anti-diabetic, gynecological, pain/analgesics, and neuro/CNS categories. The company has introduced over 21 first-in-India formulations and operates 7 marketing divisions with a 5,100-strong front-line sales force distributing through India's stockist secondary sales network.

Product overview

ARISTO Pharmaceuticals is a top-11 Indian pharmaceutical company (ranked 11th in Indian Pharma Market per IQVIA MAT Mar'25) with revenues of Rs. 5700.38 Crores and market share of 2.90%. The company operates with 7 marketing divisions and maintains a focused product portfolio across therapeutic segments. Its core products include antibiotics (Monocef, Mikacin, Monocef-SB, Montaz, Monocef-O, Mero, Mega-CV), gastrointestinal treatments (Pantop, Pantop-D, Aristozzyme), respiratory products (Montina-L), and cardiovascular medications (Telvas). The company has introduced 21 first-in-India formulations demonstrating innovation focus. Recent additions include ProGG probiotic (L. rhamnosus GG) launched via technical partnership with Chr. Hansen, Denmark, along with various other products. ARISTO ranks 3rd in its covered market and 5th in prescription audit (SMSRC), reflecting strong brand equity and medical fraternity trust.

Differentiator

Problem solved

Functional benefit

Brands

• ProGG: World's No.1 probiotic L. rhamnosus GG launched under technical tie-up with Chr. Hansen, Denmark. First Indian brand with 5 billion LGG.
• Monocef
• Pantop
• Mikacin
• Pantop-D
• Monocef-SB
• Montaz
• Monocef-O
• Mero
• Mega-CV
• Aristozyme
• Montina-L
• Telvas

Products and services

• Monocef Ceftriaxone antibiotic formulation; the first Ceftriaxone introduced in India, marketed to physicians and distributed via stockists for treatment of bacterial infections.
• Pantop Pantoprazole proton-pump inhibitor for gastrointestinal conditions such as acid reflux and peptic ulcers; prescribed by physicians and dispensed through stockists.
• Mikacin Amikacin antibiotic; the first Amikacin formulation introduced in India, indicated for serious bacterial infections and prescribed by hospital practitioners and specialists.
• Pantop-D Pantoprazole + Domperidone combination for gastrointestinal conditions including GERD and dyspepsia; distributed through stockists and prescribed by gastroenterologists and general physicians.
• Monocef-SB Ceftriaxone + Sulbactam combination antibiotic for resistant bacterial infections; prescribed by specialists and stocked by hospital pharmacies.
• Montaz Ceftriaxone + Tazobactam injection; first such combination in India, used for serious bacterial infections in hospital settings.
• Monocef-O Oral Cefpodoxime antibiotic; an oral cephalosporin for bacterial infections, marketed to general physicians and pediatricians.
• Mero Meropenem carbapenem antibiotic for severe bacterial infections, primarily used in hospital and ICU settings.
• Mega-CV Amoxicillin and Clavulanic acid combination antibiotic; widely prescribed for respiratory and other bacterial infections.
• Aristozzyme Digestive enzyme (Fungal Diastase) liquid; the first such formulation in India, marketed for digestive disorders and enzyme deficiencies.
• Montina-L Levocetirizine + Montelukast combination for respiratory allergies and asthma; prescribed by pulmonologists, allergists, and general physicians.
• Telvas Telmisartan antihypertensive for cardiovascular conditions including hypertension; marketed to cardiologists and general physicians.
• ProGG L. rhamnosus GG probiotic supplement; the first Indian brand with 5 billion LGG launched under technical partnership with Chr. Hansen, Denmark, marketed for gut health.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Chr. Hansen, DenmarkcoreTechnology or Integration · 1 January 2023Technical tie-up with Chr. Hansen, Denmark for ProGG brand - World's No.1 probiotic L. rhamnosus GG. This is the first Indian brand with 5 billion LGG, positioning Aristo as a leader in the probiotic segment in India.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mankind Pharma: Ranked 4th in the Indian Pharma Market with Rs 9,942.86 Cr revenue and similar India-focused branded generics model across primary-care and specialty segments; directly comparable in therapeutic mix and channel-led GTM.
• Alkem Laboratories: Ranked 5th in IPM with Rs 8,058.38 Cr revenue; comparable Indian branded-formulations company with broad anti-infective, GI, and chronic-care coverage and similar sales-force-driven distribution.
• Torrent Pharmaceuticals: Ranked 6th in IPM (Rs 7,062.46 Cr) with a branded-generics focus in cardiac, CNS, and GI — directly overlapping Aristo's therapeutic mix and India-centric channel strategy.
• Intas Pharmaceuticals: Ranked 7th in IPM (Rs 6,919.10 Cr); comparable private Indian pharma player with multi-therapeutic branded portfolio and parallel chronic-care and acute-care exposure.
• Lupin: Ranked 8th in IPM (Rs 6,866.56 Cr) with strong anti-infective, cardiac, and respiratory presence — directly competes with Aristo in several of its top brands including cephalosporins and combinations.
• Macleods Pharmaceuticals: Ranked 9th in IPM (Rs 6,781.34 Cr); privately held India-focused branded-formulations competitor with similar anti-infective, anti-diabetic, and cardiovascular portfolio depth.
• Ipca Laboratories: Ranked 14th in IPM (Rs 4,192.82 Cr); similar India-centric branded-formulations competitor with strong anti-malarial, anti-infective, and pain-management portfolios directly overlapping Aristo's therapy mix.

Broad incumbents

• Dr. Reddy's Laboratories: Ranked 10th in IPM (Rs 6,000.69 Cr); broader incumbent with global generics, biosimilars, and proprietary products, but directly competes with Aristo in the Indian branded-generics market across multiple therapy areas.
• Zydus Cadila (Zydus Lifesciences): Ranked 12th in IPM (Rs 5,372.63 Cr) and one rung behind Aristo; broadly comparable branded-formulations portfolio plus global generics and biosimilars, directly overlapping in Indian primary-care channels.
• Glenmark Pharmaceuticals: Ranked 13th in IPM (Rs 4,420.71 Cr); broader incumbent operating in India branded generics plus global specialty and API businesses, overlapping with Aristo in dermatology, respiratory, and cardiac.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aristo-pharmaceuticals-pvt-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARISTO Pharmaceuticals